NCT04514237View on ClinicalTrials.gov

Study to Determine the Relative Bioavailability, Single and Repeat Dose Pharmacokinetics, Safety and Tolerability of BOS172767 Enantiomers in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 12, 2019

Primary Completion Date

January 22, 2020

Study Completion Date

January 22, 2020

Conditions
Healthy Participants
Interventions
DRUG

BOS172767 enantiomer E1 or E2

Oral tablets

DRUG

Placebo

Oral tablets

Trial Locations (1)

Unknown

Quotient Sciences, Nottingham

Sponsors
All Listed Sponsors
lead

Boston Pharmaceuticals

INDUSTRY